turner-protocolandrationale-2019.pdf (302.67 kB)
Download file

Protocol and rationale: a 24-week double-blind, randomized, placebo controlled trial of the efficacy of adjunctive garcinia mangostanaLinn. (mangosteen) pericarp for schizophrenia

Download (302.67 kB)
journal contribution
posted on 2019-05-31, 00:00 authored by Alyna TurnerAlyna Turner, John J McGrath, Olivia DeanOlivia Dean, Seetal DoddSeetal Dodd, Andrea Baker, Susan M Cotton, James G Scott, Bianca KavanaghBianca Kavanagh, Melanie AshtonMelanie Ashton, Adam WalkerAdam Walker, Eleanor Brown, Michael BerkMichael Berk
Objective: : Garcinia mangostana Linn., commonly known as mangosteen, is a tropical fruit with a thick pericarp rind containing bioactive compounds that may be beneficial as an adjunctive treatment for schizophrenia. The biological underpinnings of schizophrenia are believed to involve altered neurotransmission, inflammation, redox systems, mitochondrial dysfunction, and neurogenesis. Mangosteen pericarp contains xanthones which may target these biological pathways and improve symptoms; this is supported by preclinical evidence. Here we outline the protocol for a double- blind randomized placebo-controlled trial evaluating the efficacy of adjunctive mangosteen pericarp (1,000 mg/day), compared to placebo, in the treatment of schizophrenia. Methods: : We aim to recruit 150 participants across two sites (Geelong and Brisbane). Participants diagnosed with schizophrenia or schizoaffective disorder will be randomized to receive 24 weeks of either adjunctive 1,000 mg/day of mangosteen pericarp or matched placebo, in addition to their usual treatment. The primary outcome measure is mean change in the Positive and Negative Symptom Scale (total score) over the 24 weeks. Secondary outcomes include positive and negative symptoms, general psychopathology, clinical global severity and improvement, depressive symptoms, life satisfaction, functioning, participants reported overall improvement, substance use, cognition, safety and biological data. A 4-week post treatment interview at week 28 will explore post-discontinuations effects. Results: : Ethical and governance approvals were gained and the trial commenced. Conclusion: : A positive finding in this study has the potential to provide a new adjunctive treatment option for people with schizophrenia and schizoaffective disorder. It may also lead to a greater understanding of the pathophysiology of the disorder.



Clinical psychopharmacology and neuroscience






297 - 307


Korean College of Neuropsychopharmacology


Seoul, South Korea





Publication classification

C1 Refereed article in a scholarly journal

Copyright notice

2019, The Korean College of Neuropsychopharmacology